Toggle Main Menu Toggle Search

Open Access padlockePrints

Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

Lookup NU author(s): Dr Paula Iruzubieta, Professor Quentin AnsteeORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).


Abstract

© 2022 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. Background and Aims: We previously identified subsets of patients with NAFLD with different metabolic phenotypes. Here we align metabolomic signatures with cardiovascular disease (CVD) and genetic risk factors. Approach and Results: We analyzed serum metabolome from 1154 individuals with biopsy-proven NAFLD, and from four mouse models of NAFLD with impaired VLDL-triglyceride (TG) secretion, and one with normal VLDL-TG secretion. We identified three metabolic subtypes: A (47%), B (27%), and C (26%). Subtype A phenocopied the metabolome of mice with impaired VLDL-TG secretion; subtype C phenocopied the metabolome of mice with normal VLDL-TG; and subtype B showed an intermediate signature. The percent of patients with NASH and fibrosis was comparable among subtypes, although subtypes B and C exhibited higher liver enzymes. Serum VLDL-TG levels and secretion rate were lower among subtype A compared with subtypes B and C. Subtype A VLDL-TG and VLDL–apolipoprotein B concentrations were independent of steatosis, whereas subtypes B and C showed an association with these parameters. Serum TG, cholesterol, VLDL, small dense LDL5,6, and remnant lipoprotein cholesterol were lower among subtype A compared with subtypes B and C. The 10-year high risk of CVD, measured with the Framingham risk score, and the frequency of patatin-like phospholipase domain-containing protein 3 NAFLD risk allele were lower in subtype A. Conclusions: Metabolomic signatures identify three NAFLD subgroups, independent of histological disease severity. These signatures align with known CVD and genetic risk factors, with subtype A exhibiting a lower CVD risk profile. This may account for the variation in hepatic versus cardiovascular outcomes, offering clinically relevant risk stratification.


Publication metadata

Author(s): Martinez-Arranz I, Bruzzone C, Noureddin M, Gil-Redondo R, Minchole I, Bizkarguenaga M, Arretxe E, Iruarrizaga-Lejarreta M, Fernandez-Ramos D, Lopitz-Otsoa F, Mayo R, Embade N, Newberry E, Mittendorf B, Izquierdo-Sanchez L, Smid V, Arnold J, Iruzubieta P, Perez Castano Y, Krawczyk M, Marigorta UM, Morrison MC, Kleemann R, Martin-Duce A, Hayardeny L, Vitek L, Bruha R, Aller de la Fuente R, Crespo J, Romero-Gomez M, Banales JM, Arrese M, Cusi K, Bugianesi E, Klein S, Lu SC, Anstee QM, Millet O, Davidson NO, Alonso C, Mato JM

Publication type: Article

Publication status: Published

Journal: Hepatology

Year: 2022

Pages: Epub ahead of print

Online publication date: 26/02/2022

Acceptance date: 15/02/2022

Date deposited: 29/03/2022

ISSN (print): 0270-9139

ISSN (electronic): 1527-3350

Publisher: John Wiley and Sons Inc.

URL: https://doi.org/10.1002/hep.32427

DOI: 10.1002/hep.32427

PubMed id: 35220605


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
1191145
777377European Commission
825510
AFB170005
ANID ACE 210009
CON14/00129
CPII19/00008
HL151328
HR17-00601
KK-2020/00008
PMC13
R01DK119437
SAF2017-88041-R
SEV-2016-0644
UL1TR002345
P30DK52574
P30DK56341
PI15/01132
PI18/01075
PMC15
R01DK123763
RVO-VFN64165/2020

Share